Oppenheimer Releases a Buy Rating on Vascular Biogenics (VBLT)

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Vascular Biogenics (VBLTResearch Report) today and set a price target of $5.00. The company’s shares closed last Tuesday at $1.96.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 39.5% and a 45.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Rocket Pharmaceuticals, and Sensei Biotherapeutics.

Vascular Biogenics has an analyst consensus of Strong Buy, with a price target consensus of $5.00.

See today’s analyst top recommended stocks >>

Based on Vascular Biogenics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $205K and GAAP net loss of $7.26 million. In comparison, last year the company earned revenue of $126K and had a GAAP net loss of $5.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.